title: Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin's lymphoma.
abstract: Posterior reversible encephalopathy syndrome (PRES) is characterized by a group of central nervous system related symptoms. Diagnosis is usually made by computed tomography or magnetic resonance imaging. Common causes can be arterial hypertension, sepsis, autoimmune disorders, and medications. We report PRES in a relapsed Hodgkin's Lymphoma patient after a dose of pembrolizumab.
authors.affiliation: 1 Northside Hospital, Atlanta, GA, USA.
authors.forename: Justin
authors.initials: J
authors.lastname: LaPorte
authors.affiliation: 2 Blood and Marrow Transplant Group of Georgia, Atlanta, GA, USA.
authors.forename: Melhem
authors.initials: M
authors.lastname: Solh
authors.affiliation: 1 Northside Hospital, Atlanta, GA, USA.
authors.forename: Serge
authors.initials: S
authors.lastname: Ouanounou
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D054038:Posterior Leukoencephalopathy Syndrome / Q000188:drug therapy*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C582435:pembrolizumab
keywords: Hodgkin; Keytruda; PRES; encephalopathy syndrome; pembrolizumab; posterior reversible